Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EVISTA vs NOLVADEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective estrogen receptor modulator (SERM) that binds to estrogen receptors, acting as an agonist in bone and antagonist in breast and uterine tissues.
NOLVADEX (tamoxifen citrate) is a nonsteroidal selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors in breast tissue, thereby blocking estrogen-mediated cell proliferation. It also has partial agonist activity in other tissues such as bone and endometrium.
Treatment and prevention of osteoporosis in postmenopausal women,Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis,Reduction in risk of invasive breast cancer in postmenopausal women at high risk for breast cancer
Treatment of metastatic breast cancer in women and men,Adjuvant treatment of breast cancer in women with node-positive or node-negative disease following primary surgery,Reduction of breast cancer incidence in high-risk women (pre- and postmenopausal) for primary prevention,Reduction of contralateral breast cancer risk in women with ductal carcinoma in situ (DCIS) or prior breast cancer,Off-label: Induction of ovulation in anovulatory infertility; treatment of gynecomastia; reduction of breast cancer risk in BRCA mutation carriers
60 mg orally once daily.
20-40 mg orally once daily; for breast cancer, 20 mg/day. For adjuvant therapy, 20 mg/day for 5 years. For ductal carcinoma in situ, 20 mg/day for 5 years. For reduction of breast cancer incidence in high-risk women, 20 mg/day for 5 years.
Terminal elimination half-life is approximately 32.5 hours (range 27-39 hours) for raloxifene and its glucuronide conjugates; clinically relevant for once-daily dosing.
Tamoxifen: 5-7 days (terminal). N-desmethyltamoxifen (active metabolite): 14 days. Steady-state achieved in 3-4 weeks.
Extensively metabolized in the liver via glucuronidation (UGT1A1, UGT1A8, UGT1A9) and CYP3A4-mediated oxidation.
Extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2D6 (to active metabolite endoxifen) and CYP3A4, with contributions from CYP2B6, CYP2C9, and CYP2C19. Undergoes glucuronidation and sulfation. Endoxifen is further metabolized by CYP3A4.
Raloxifene undergoes extensive glucuronidation; <0.1% excreted unchanged in urine. Approximately 95% is excreted in feces over 5 days (primarily as glucuronide conjugates). Renal elimination of unchanged drug is negligible (<0.1%).
Primarily fecal (65%) as conjugates; renal excretion accounts for approximately 25% as metabolites and <0.5% as unchanged drug. Biliary elimination contributes 10%.
>95% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.
>99% bound primarily to albumin.
Apparent Vd/F is approximately 1000-1500 L (not weight-based; extensive tissue distribution).
50-60 L/kg, indicating extensive tissue distribution (e.g., breast, liver, uterus).
Absolute oral bioavailability is approximately 2% due to extensive first-pass glucuronidation; systemic exposure is dose-proportional.
Oral: Approximately 100% after first pass due to extensive hepatic metabolism; absolute bioavailability is nearly complete but variable.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), use with caution; no specific guidelines, consider reduced dose.
Contraindicated in patients with Child-Pugh Class B or C hepatic impairment. No specific dose adjustment recommended for Child-Pugh Class A, but use with caution.
Contraindicated in Child-Pugh class C. For Child-Pugh class B, reduce dose by 50% (e.g., 20 mg every other day). For Child-Pugh class A, no adjustment needed.
Safety and efficacy not established in pediatric patients; no recommended dose.
Safety and efficacy not established in pediatric patients for FDA-approved indications. Off-label use for gonadotropin-independent precocious puberty: 20 mg orally once daily (monitor for potential risks).
No specific dose adjustment required; use standard adult dosing. Consider increased risk of venous thromboembolism and stroke in elderly women.
No specific dose adjustment recommended based on age alone; dosing same as adults. Monitor for increased risk of thromboembolic events, endometrial cancer, and cataracts. Start at lower end of dosing range (20 mg/day) if frail or with comorbidities.
Increased risk of venous thromboembolism (VTE) and death from stroke. Not for use in women with active or history of VTE, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis. Not for use in women with atrial fibrillation or other conditions that increase risk of stroke.
WARNING: SERIOUS AND LIFE-THREATENING EVENTS - NOLVADEX has been associated with an increased risk of uterine malignancies (including endometrial cancer and uterine sarcoma), stroke, and pulmonary embolism. These risks increase with duration of therapy and patient age. Use only when benefit outweighs risk. Educate patients about symptoms of these events and seek prompt medical attention.
Risk of VTE; discontinue if VTE occurs. Risk of stroke; discontinue if stroke occurs or for prolonged immobilization. May increase risk of endometrial cancer; monitor for abnormal bleeding. Not for premenopausal women. Use with caution in patients with hepatic impairment or cholestasis. May increase triglycerides; monitor in patients with history of hypertriglyceridemia.
Increased risk of endometrial cancer, uterine sarcoma, and other uterine malignancies; perform baseline gynecologic exam and monitor for abnormal bleeding,Increased risk of thromboembolic events (DVT, PE, stroke); avoid in patients with history of thromboembolism,Hepatotoxicity: elevated liver enzymes, hepatitis, and hepatic steatosis; monitor periodic liver function tests,Ocular effects: cataracts, retinopathy; perform periodic eye exams,Hypercalcemia: may occur in patients with bone metastases; monitor serum calcium,Bone density loss: may cause decreased bone mineral density in premenopausal women; consider calcium and vitamin D supplementation,QT prolongation: use caution with other QT-prolonging drugs or electrolyte imbalances,Fetal harm: can cause fetal harm if used during pregnancy; advise women of childbearing age to use effective contraception
Active or history of VTE, pregnancy, women who may become pregnant, lactation, hypersensitivity to raloxifene, or any component of the formulation.
History of deep vein thrombosis (DVT) or pulmonary embolism (PE),History of cerebral vascular accident (CVA) or transient ischemic attack (TIA),Known hypersensitivity to tamoxifen or any component of the formulation,Pregnancy (avoid use unless potential benefit justifies potential risk to fetus); use in women of childbearing age only with adequate contraception,Concurrent use with warfarin or other coumarin-type anticoagulants (relative contraindication due to increased bleeding risk),Severe hepatic impairment (Child-Pugh class C)
Avoid grapefruit and grapefruit juice as they may increase raloxifene levels. No other significant food interactions.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4, potentially altering tamoxifen metabolism. Avoid St. John's wort. No other specific dietary restrictions, but maintain a balanced diet. Alcohol should be limited due to increased risk of liver enzyme elevation.
Pregnancy Category X. Raloxifene is contraindicated in pregnancy. In animal studies, raloxifene caused fetal abnormalities including skeletal malformations and cardiovascular defects. Human data are unavailable due to contraindication; use in pregnancy may cause fetal harm.
Nolvadex (tamoxifen) is classified as FDA Pregnancy Category D. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience. First trimester exposure is associated with spontaneous abortions, birth defects (including craniofacial, genital, and skeletal anomalies), and fetal death. Second and third trimester exposure may cause fetal harm including pulmonary hypoplasia and growth retardation. Use is contraindicated during pregnancy.
Raloxifene is excreted in rat milk; no human data available. The M/P ratio is unknown. Due to potential adverse effects on the infant, breastfeeding is not recommended during therapy.
Tamoxifen is excreted in human milk. The milk-to-plasma ratio (M/P) is approximately 0.5-0.75. Due to potential serious adverse reactions in nursing infants, including hormonal effects and carcinogenicity, breastfeeding is not recommended during tamoxifen therapy and for at least 3 months after the last dose.
No dosing adjustments are applicable as raloxifene is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy do not inform dose modifications due to the contraindication.
Tamoxifen is contraindicated in pregnancy; therefore, dose adjustments are not applicable. If pregnancy occurs during therapy, discontinue tamoxifen immediately and manage with alternative therapies. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered hepatic metabolism) may reduce tamoxifen exposure, but no dose adjustments have been studied or recommended due to risk.
Monitor for venous thromboembolism; avoid in patients with active or history of VTE. May increase risk of stroke in postmenopausal women with coronary heart disease. No significant effect on breast cancer incidence. Administer with caution in hepatic impairment. Discontinue prior to prolonged immobilization or surgery.
NOLVADEX (tamoxifen) is a selective estrogen receptor modulator (SERM) indicated for the treatment and prevention of breast cancer. Monitor for endometrial hyperplasia and thromboembolic events. Use with caution in patients with history of DVT/PE. CYP2D6 inhibitors (e.g., paroxetine) reduce conversion to active metabolite endoxifen; avoid coadministration. Tamoxifen can cause tumor flare in bone metastases. Discontinue 2-3 months before attempting pregnancy due to long half-life. Regular gynecologic exams and ophthalmologic monitoring recommended.
Take once daily with or without food.,Report any signs of blood clots (leg pain/swelling, sudden chest pain, shortness of breath).,May cause hot flashes, leg cramps, or flu-like symptoms.,Avoid pregnancy; not indicated for premenopausal women.,Requires adequate calcium and vitamin D intake.
Take exactly as prescribed; do not skip doses.,Report any unusual vaginal bleeding, pelvic pain, or changes in vision immediately.,Avoid grapefruit juice as it may affect drug levels.,Use effective non-hormonal contraception during therapy and for 2 months after stopping.,Do not take St. John's wort or other herbal supplements without consulting your doctor.,Report leg swelling, chest pain, or shortness of breath promptly.,May cause hot flashes, nausea, or fatigue; these are not reasons to stop without consulting your doctor.,Attend all scheduled gynecologic and eye exams.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EVISTA vs NOLVADEX, answered by our medical review team.
EVISTA is a Selective Estrogen Receptor Modulator that works by Selective estrogen receptor modulator (SERM) that binds to estrogen receptors, acting as an agonist in bone and antagonist in breast and uterine tissues.. NOLVADEX is a Selective Estrogen Receptor Modulator that works by NOLVADEX (tamoxifen citrate) is a nonsteroidal selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors in breast tissue, thereby blocking estrogen-mediated cell proliferation. It also has partial agonist activity in other tissues such as bone and endometrium.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EVISTA and NOLVADEX depend on the specific clinical indication. These are both Selective Estrogen Receptor Modulator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EVISTA is: 60 mg orally once daily.. The standard adult dose of NOLVADEX is: 20-40 mg orally once daily; for breast cancer, 20 mg/day. For adjuvant therapy, 20 mg/day for 5 years. For ductal carcinoma in situ, 20 mg/day for 5 years. For reduction of breast cancer incidence in high-risk women, 20 mg/day for 5 years.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EVISTA and NOLVADEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EVISTA is classified as Category C. Pregnancy Category X. Raloxifene is contraindicated in pregnancy. In animal studies, raloxifene caused fetal abnormalities including skeletal malformations and cardiovascular defec. NOLVADEX is classified as Category C. Nolvadex (tamoxifen) is classified as FDA Pregnancy Category D. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing expe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.